Covid 19 Research using Clinical Trials (Home Page)
Clazakizumab 25 mgWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (1)
|
Name (Synonyms) |
Correlation |
D007239 | Infection NIH | 0.08 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
In this study clazakizumab will be administered to patients with life-threatening COVID-19
infection manifest by pulmonary failure and a clinical picture consistent with a cytokine
storm syndrome. This is a single-center randomized, double-blind, placebo-controlled trial in
which 30 patients will be enrolled and randomly assigned in a 1:1:1 ratio to three study arms
that will receive clazakizumab at a dose of 12.5 mg, 25 mg or placebo
NCT04343989 COVID-19 Drug: Clazakizumab 12.5 mg Drug: Clazakizumab 25 mg Other: Placebo
Primary Outcomes
Measure: Incidence of serious adverse events associated with clazakizumab or placebo Time: 60 days
Secondary Outcomes
Measure: Incidence of intubation
Time: 14 days
Measure: Time to extubation
Time: 14 days
Measure: Length of ICU stay
Time: 14 days
Measure: Number of patients who present a decrease in C-reactive protein
Time: 14 days
Description: Assessed at 28 and 60 days
Measure: Patient survival
Time: 60 days
No related HPO nodes (Using clinical trials)